Latest Articles

Publication Date
Oral Gonadotropin-Releasing Hormone Antagonists for the Treatment of Endometriosis-Associated Pain: A Systematic Review and Meta-Analysis.

To evaluate the efficacy of oral gonadotropin-releasing hormone (GnRH) antagonists versus placebo for treatment of endometriosis-associated pain and to compare individual antagonists indirectly for dysmenorrhea and non-menstrual pelvic pain.

Published: April 21, 2026, midnight
Effectiveness of 12-month GnRH antagonist treatment for endometriosis-associated pain: driven by reduction in uterine bleeding?

Published: April 8, 2026, midnight
Linzagolix, with and without add-back therapy, in women with endometriosis-associated pain: results from EDELWEISS 6, a double-blind randomized extension and withdrawal study.

Was the efficacy of linzagolix, observed at 6 months in women with endometriosis-associated pain, maintained when administered for an additional 6 months?

Published: April 8, 2026, midnight
Single-Dose Bioequivalence Study of Elagolix Tablets 200 mg (Test Product) and Elagolix Tablets 200 mg (Reference Product) in Healthy Non-Pregnant, Non-Lactating Premenopausal Female Subjects Under Fasting Conditions.

Elagolix is a short-acting oral gonadotropin-releasing hormone antagonist utilized for treating endometriosis-associated pain by rapidly suppressing gonadotropins and estradiol. Although well characterized in Western populations, clinical data regarding its use …

Published: April 2, 2026, midnight
Synergistic effects of melatonin and dienogest on pain relief in endometriosis: a randomized controlled trial.

Endometriosis affects 5-10% of reproductive-aged women and is characterized by chronic pelvic pain, dysmenorrhea, dyspareunia, and infertility. Standard hormonal therapies, such as dienogest, effectively manage symptoms, but are often associated …

Published: March 31, 2026, midnight
Exposure to Green Light-emitting Diodes Alleviates Endometriosis-associated Pain in Mice with Induced Deep Endometriosis.

Published: March 19, 2026, midnight
The #Enzian Classification as a Predictor of Hormonal Therapy Response in Endometriosis-Associated Pain: A Retrospective Cohort Study in a Referral Center.

To evaluate whether ultrasound-based #Enzian classification predicts pain profiles and response to hormonal therapy in patients with endometriosis. Endometriosis is a chronic inflammatory disease affecting 10% of reproductive-age women, often …

Published: March 11, 2026, midnight
Comparison of Letrozole with Elagolix for the Management of Endometriosis-Associated Pain: A Quasi-Experimental Study.

To compare the efficacy of Letrozole and Elagolix in the medical management of endometriosis-associated pain Study Design: A quasi-experimental study. Place and Duration of the Study: Department of Obstetrics and …

Published: March 6, 2026, midnight
Efficacy and tolerability of elagolix in adolescents and young adults with endometriosis: a small, single-center retrospective cohort study.

To evaluate the efficacy and tolerability of the gonadotropin-releasing hormone antagonist elagolix for endometriosis-associated pain symptoms in adolescents and young adults (AYA).

Published: Feb. 14, 2026, midnight
Atypical gelation of Elagolix sodium in aqueous media: Mechanistic insights and Inhibition via coamorphization.

Elagolix sodium (ELS), a non-peptide oral gonadotropin-releasing hormone receptor (GnRH) antagonist approved for the treatment of endometriosis-associated pain, displays atypical gelation in aqueous environments along with challenging physical properties such …

Published: Feb. 12, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!